Gland Pharma Limited

NSE GLAND.NS

Gland Pharma Limited EBITDA for the year ending March 31, 2024: USD 180.23 M

Gland Pharma Limited EBITDA is USD 180.23 M for the year ending March 31, 2024, a 22.55% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Gland Pharma Limited EBITDA for the year ending March 31, 2023 was USD 147.07 M, a -35.60% change year over year.
  • Gland Pharma Limited EBITDA for the year ending March 31, 2022 was USD 228.38 M, a 16.37% change year over year.
  • Gland Pharma Limited EBITDA for the year ending March 31, 2021 was USD 196.25 M, a 35.11% change year over year.
  • Gland Pharma Limited EBITDA for the year ending March 31, 2020 was USD 145.26 M, a 30.74% change year over year.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Loading...
NSE: GLAND.NS

Gland Pharma Limited

CEO Mr. Srinivas Sadu
IPO Date Nov. 20, 2020
Location India
Headquarters Plot No. 11 & 84, TSIIC Phase: IV
Employees 4,217
Sector Health Care
Industries
Description

Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its products under various therapeutic categories, such as anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, pain management, hormones and related drugs, fertility supplements, Gnrh agonists and antagonists, anti-neoplastic, gynecological, neurological and central nervous system, respiratory, blood related, ophthalmological and otological, pain/analgesics, orthopedics, hematinic, vitamins/minerals/nutrients, and others. The company also provides contract development services. It sells its products primarily under a business to business in the United States, Europe, Canada, Australia, India, and internationally. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited is a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Similar companies

CAMS.NS

Computer Age Management Services Limited

USD 48.75

-1.31%

LALPATHLAB.NS

Dr. Lal PathLabs Limited

USD 32.39

-1.98%

ROUTE.NS

Route Mobile Limited

USD 15.30

3.18%

LAURUSLABS.NS

Laurus Labs Limited

USD 6.56

1.75%

ALKEM.NS

Alkem Laboratories Limited

USD 60.83

0.86%

StockViz Staff

January 15, 2025

Any question? Send us an email